These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9052286)

  • 1. Hemofiltration during cardiopulmonary bypass: the effect on anti-Xa and anti-IIa heparin activity.
    Despotis GJ; Levine V; Filos KS; Joiner-Maier D; Joist JH
    Anesth Analg; 1997 Mar; 84(3):479-83. PubMed ID: 9052286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole blood heparin concentrations do not correlate with plasma antifactor Xa heparin concentrations in pediatric patients undergoing cardiopulmonary bypass.
    Gruenwald C; de Souza V; Chan AK; Andrew M
    Perfusion; 2000 Jun; 15(3):203-9. PubMed ID: 10866421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass.
    Guzzetta NA; Monitz HG; Fernandez JD; Fazlollah TM; Knezevic A; Miller BE
    Anesth Analg; 2010 Jul; 111(1):173-9. PubMed ID: 20519414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations.
    Despotis GJ; Summerfield AL; Joist JH; Goodnough LT; Santoro SA; Spitznagel E; Cox JL; Lappas DG
    J Thorac Cardiovasc Surg; 1994 Dec; 108(6):1076-82. PubMed ID: 7983877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of heparin concentration in whole blood with the Hepcon/HMS device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X.
    Hardy JF; Bélisle S; Robitaille D; Perrault J; Roy M; Gagnon L
    J Thorac Cardiovasc Surg; 1996 Jul; 112(1):154-61. PubMed ID: 8691862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin assays.
    Murray DJ; Brosnahan WJ; Pennell B; Kapalanski D; Weiler JM; Olson J
    J Cardiothorac Vasc Anesth; 1997 Feb; 11(1):24-8. PubMed ID: 9058215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The plasma supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: a pilot investigation.
    Koster A; Despotis G; Gruendel M; Fischer T; Praus M; Kuppe H; Levy JH
    Anesth Analg; 2002 Jul; 95(1):26-30, table of contents. PubMed ID: 12088937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimum protamine dose required to neutralize heparin in cardiac surgery: a single-centre, prospective, observational cohort study.
    Taneja R; Szoke DJ; Hynes Z; Jones PM
    Can J Anaesth; 2023 Feb; 70(2):219-227. PubMed ID: 36471142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new method of measuring heparin levels in whole blood by protamine titration using a heparin-responsive electrochemical sensor.
    Wahr JA; Yun JH; Yang VC; Lee LM; Fu B; Meyerhoff ME
    J Cardiothorac Vasc Anesth; 1996 Jun; 10(4):447-50. PubMed ID: 8776635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation.
    Despotis GJ; Joist JH; Hogue CW; Alsoufiev A; Kater K; Goodnough LT; Santoro SA; Spitznagel E; Rosenblum M; Lappas DG
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):46-54. PubMed ID: 7609568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protamine requirements in cardiac surgery: effect of changes in the heparin reference standard.
    Taneja R; Berry L; Pappu U; Stitt L; Sayal P; Allen P; Hoogendoorn H; Chan A
    J Cardiothorac Vasc Anesth; 2014 Oct; 28(5):1227-32. PubMed ID: 25281041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heparin monitoring during cardiopulmonary bypass surgery using the one-step point-of-care whole blood anti-factor-Xa clotting assay heptest-POC-Hi.
    Hellstern P; Bach J; Simon M; Saggau W
    J Extra Corpor Technol; 2007 Jun; 39(2):81-6. PubMed ID: 17672188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of aprotinin on activated clotting time, whole blood and plasma heparin measurements.
    Despotis GJ; Joist JH; Joiner-Maier D; Alsoufiev AL; Triantafillou AN; Goodnough LT; Santoro SA; Lappas DG
    Ann Thorac Surg; 1995 Jan; 59(1):106-11. PubMed ID: 7529483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges with heparin-based anticoagulation during cardiopulmonary bypass in children: Impact of low antithrombin activity.
    Manlhiot C; Gruenwald CE; Holtby HM; Brandão LR; Chan AK; Van Arsdell GS; McCrindle BW
    J Thorac Cardiovasc Surg; 2016 Feb; 151(2):444-50. PubMed ID: 26553458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin clearance during continuous veno-venous haemofiltration.
    Singer M; McNally T; Screaton G; Mackie I; Machin S; Cohen SL
    Intensive Care Med; 1994; 20(3):212-5. PubMed ID: 8014289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin monitoring during cardiac surgery. Part 1: Validation of whole-blood heparin concentration and activated clotting time.
    Raymond PD; Ray MJ; Callen SN; Marsh NA
    Perfusion; 2003 Sep; 18(5):269-76. PubMed ID: 14604242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Factor Xa inhibitory assay to detect plasma heparin concentrations during and after cardiopulmonary bypass].
    Wang L; Li L; Shi Y; Fang Q
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Apr; 34(2):310-2. PubMed ID: 12947723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of ACT as measured with three commercially available devices with circulating heparin level during cardiac surgery.
    Niles SD; Sutton RG; Ploessl J; Pennell B
    J Extra Corpor Technol; 1995 Dec; 27(4):197-200. PubMed ID: 10172651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery.
    Taneja R; Marwaha G; Sinha P; Quantz M; Stitt L; Gao R; Subramanian S; Schaus M; Keeney M; Chin-Yee I; Murkin J
    Can J Anaesth; 2009 Jul; 56(7):489-96. PubMed ID: 19408066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.